Indolent Systemic Mastocytosis

hematologic malignancy

Identifier: CI-CAN-00007849
Entity page: /cancer/indolent-systemic-mastocytosis ↗
Edges: 18

Neighbours: 3 drugs15 trials
Drawn: 18 of 18 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Indolent Systemic Mastocytosis investigated in trials for …INVESTIGATED_IN_TRIALSderived3 of 3
→ investigated in trials for	Avapritinibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Indolent Systemic Mastocytosis	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Masitinibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants

Indolent Systemic Mastocytosis studied in …STUDIED_INderived15 of 15show fewer
→ studied in	NCT04910685Phase 2/Phase 3 · recruiting (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07264959recruiting An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT06210698recruiting Angioedema Biomarker Research Study · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT05186753Phase 2 · active not recruiting (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis · condition mapped ALIAS · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07255638recruiting A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT03731260Phase 2 · active not recruiting (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT03770273Phase 2 · completed Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT04655118Phase 2 · unknown Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT05923372unknown Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT04333108Phase 3 · unknown Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT00814073Phase 3 · completed Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT03632811completed Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT02808793Phase 1 · completed A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT02478957Phase 2 · completed Treatment of Indolent Systemic Mastocytosis With PA101 · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT01920204Phase 2 · unknown Midostaurin in Indolent Systemic Mastocytosis · condition mapped ONTOLOGY_EXACT · 15 trials mapped (6 active)	—	—	Indolent Systemic Mastocytosis	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains